- Home
- PMVP vs CMRX Comparison
PMVP vs CMRX Comparison
Compare PMVP & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- CMRX
- Stock Information
- Founded
- PMVP 2013
- CMRX 2000
- Country
- PMVP United States
- CMRX United States
- Employees
- PMVP N/A
- CMRX N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- CMRX Health Care
- Exchange
- PMVP Nasdaq
- CMRX Nasdaq
- Market Cap
- PMVP 85.5M
- CMRX 77.0M
- IPO Year
- PMVP 2020
- CMRX 2013
- Fundamental
- Price
- PMVP $1.65
- CMRX $0.93
- Analyst Decision
- PMVP Strong Buy
- CMRX Strong Buy
- Analyst Count
- PMVP 4
- CMRX 1
- Target Price
- PMVP $5.75
- CMRX $11.00
- AVG Volume (30 Days)
- PMVP 185.0K
- CMRX 119.4K
- Earning Date
- PMVP 11-07-2024
- CMRX 11-08-2024
- Dividend Yield
- PMVP N/A
- CMRX N/A
- EPS Growth
- PMVP N/A
- CMRX N/A
- EPS
- PMVP N/A
- CMRX N/A
- Revenue
- PMVP N/A
- CMRX $144,000.00
- Revenue This Year
- PMVP N/A
- CMRX $3,040.12
- Revenue Next Year
- PMVP N/A
- CMRX N/A
- P/E Ratio
- PMVP N/A
- CMRX N/A
- Revenue Growth
- PMVP N/A
- CMRX N/A
- 52 Week Low
- PMVP $1.33
- CMRX $0.75
- 52 Week High
- PMVP $3.47
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- PMVP 60.86
- CMRX 60.78
- Support Level
- PMVP $1.63
- CMRX $0.80
- Resistance Level
- PMVP $1.69
- CMRX $0.98
- Average True Range (ATR)
- PMVP 0.07
- CMRX 0.05
- MACD
- PMVP 0.01
- CMRX 0.01
- Stochastic Oscillator
- PMVP 52.65
- CMRX 83.33
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.